Eptacog Alfa Market

Eptacog alfa?(activated) is a recombinant activated factor VII (rFVIIa) used for the treatment and prevention of bleeding episodes in patients with congenital hemophilia with inhibitors.

Eptacog Alfa Market contains market size and forecasts of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) in global, including the following market information:

Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) companies in 2021 (%)

The global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

60 KIU Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) include BMS, Generium, Novo Nordisk, Shire (Baxter), Bayer, CSL, Pfizer, Grifols and Biogen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Segment Percentages, by Type, 2021 (%)

60 KIU

50 KIU

Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Segment Percentages, by Application, 2021 (%)

Bleeding

Surgery Assisted

Glanzmann Plateletasthenia

Hemophilia B

Hemophilia A

Head Trauma

Others

Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) revenues share in global market, 2021 (%)

Key companies Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

BMS

Generium

Novo Nordisk

Shire (Baxter)

Bayer

CSL

Pfizer

Grifols

Biogen

Octapharma

NovoNordisk

Greencross

Kedrion

BPL

Hualan Bio

RAAS

Suzhou Alphamab